このエントリーをはてなブックマークに追加
ID 60824
著者
Tomoda, Takeshi Department of Gastroenterology and Hepatology, Okayama University Hospital ORCID
Kato, Hironari Department of Gastroenterology and Hepatology, Okayama University Hospital ORCID Kaken ID researchmap
Miyamoto, Kazuya Department of Gastroenterology and Hepatology, Okayama University Hospital
Matsumi, Akihiro Department of Gastroenterology and Hepatology, Okayama University Hospital
Ueta, Eijiro Department of Gastroenterology and Hepatology, Okayama University Hospital
Fujii, Yuuki Department of Gastroenterology and Hepatology, Okayama University Hospital
Saragai, Yousuke Department of Gastroenterology and Hepatology, Okayama University Hospital
Yamazaki, Tatsuhiro Department of Gastroenterology and Hepatology, Okayama University Hospital
Uchida, Daisuke Department of Gastroenterology and Hepatology, Okayama University Hospital ORCID Kaken ID researchmap
Matsumoto, Kazuyuki Department of Gastroenterology and Hepatology, Okayama University Hospital ORCID Kaken ID publons
Horiguchi, Shigeru Department of Gastroenterology and Hepatology, Okayama University Hospital
Tsutsumi, Koichiro Department of Gastroenterology and Hepatology, Okayama University Hospital ORCID Kaken ID researchmap
Okada, Hiroyuki Department of Gastroenterology and Hepatology, Okayama University Hospital Kaken ID publons researchmap
抄録
Background
Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP). Rectal administration of non‐steroidal anti‐inflammatory drugs (NSAIDs) decreases the incidence of post‐ERCP pancreatitis (PEP). However, the efficacy of low dose rectal NSAIDs for preventing PEP remains controversial.
Methods
We performed a retrospective study of 301 patients with native papilla and a body weight of <50 kg who underwent ERCP between September 2010 and October 2019. After July 2016, a 25 mg dose of rectal diclofenac was routinely administered within 15 min before ERCP (NSAIDs group, n = 72) and the control group (n = 229) consisted of patients undergoing ERCP before this date without treatment. We compared the incidence of PEP between the two groups using propensity score matching.
Results
A total of 66 pairs of patients in each group were selected. The patients and procedural‐related factors were similar in both groups. In total, 15 patients (11.4%) developed PEP: 12.1% (8/66) in the NSAIDs group and 10.6% (7/66) in the control group (Odds ratio (OR) 1.2; 95% confidence interval (CI) 0.4–3.5; P = 0.78). There was no significant difference in incidence of other adverse events related to ERCP between the two groups.
Conclusions
Prophylactic administration of a 25 mg dose of rectal diclofenac did not reduce the incidence of PEP in patients with a native papilla and a body weight of <50 kg in this study and a certain dose of rectal NSAIDs, such as a 100‐mg dose, should be administered regardless of body weight to prevent PEP.
キーワード
diclofenac
low dose
post‐ERCP pancreatitis
備考
This is the peer reviewed version of the following article: Takeshi Tomoda et. al. Efficacy of low dose rectal diclofenac for preventing post‐endoscopic retrograde cholangiopancreatography pancreatitis: Propensity score‐matched analysis. Digestive Endoscopy, which has been published in final form at https://doi.org/10.1111/den.13828. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
This fulltext is available in Sep. 2021.
発行日
2020-09-02
出版物タイトル
Digestive Endoscopy
出版者
Wiley
ISSN
0915-5635
NCID
AA10907137
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
論文のバージョン
author
PubMed ID
DOI
Web of Science KeyUT
関連URL
isVersionOf https://doi.org/10.1111/den.13828